title: Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial.
authors.affiliation: Genitourinary Cancer Section, Medical Oncology Unit, Department of Clinical Medicine, Federico II University, Naples, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.affiliation: University Hospitals Urology Institute, Cleveland, OH, USA. Electronic address: ricautor@gmail.com.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Autorino
authors.affiliation: Urologic Oncology, Division of Hematology & Oncology, Department of Medicine, University of Alabama, Birmingham, AL, USA.
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen